Brain Genomics Superstruct Project
1 other identifier
observational
61
1 country
1
Brief Summary
The purpose of this study is to explore the effects of genes and genetic variation on brain structure and function. Investigators at Harvard plan to explore the relationship between candidate genes that affect cognitive performance and brain structure/function. Since brain phenotypes reflect more proximal sequelae of gene activity, neuroimaging measures may show greater sensitivity than cognitive performance to measure gene effects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2011
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2011
CompletedFirst Submitted
Initial submission to the registry
March 1, 2012
CompletedFirst Posted
Study publicly available on registry
March 13, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2015
CompletedJune 28, 2024
June 1, 2024
3.8 years
March 1, 2012
June 27, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Neuroimaging phenotype
1 day
Eligibility Criteria
Adults with Autism Spectrum Disorders ages 13 and older.
You may qualify if:
- years or older
- Subject must have a current DSM-IV diagnosis of high functioning ASD, based on past evaluations at the Bressler Clinic.
- Subjects must have a level of understanding sufficient to communicate intelligently with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.
- Each subject must understand the nature of the study. The subject must sign an IRB approved informed consent.
You may not qualify if:
- IQ \< 70 bassed on evaluation in the Bressler Clinic.
- Contraindication to MRI including presence of metal or surgical devices (plates, implants, braces or other items).
- Neuropsychiatric conditions (such as dementia) which sufficiently impair cognition such that a surrogate consent would be required.
- Neurological disorders associated with gross brain pathology (other than atrophy), e.g., stroke, tumors, or demyelinating diseases.
- Pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Massachusetts General Hospitallead
- Harvard Universitycollaborator
Study Sites (1)
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Biospecimen
Saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gagan Joshi, MD
Massachusetts General Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Investigator, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD
Study Record Dates
First Submitted
March 1, 2012
First Posted
March 13, 2012
Study Start
April 1, 2011
Primary Completion
January 1, 2015
Study Completion
January 1, 2015
Last Updated
June 28, 2024
Record last verified: 2024-06